Kaken Pharmaceutical Co. Ltd.’s license agreement with Johnson & Johnson (J&J) for signal transducer and activator of transcription (STAT)6 inhibitor KP-723 could presage further deals in STAT6, where ...

In a speech in Malacañang, without dwelling on why the historical figures were all removed, President Marcos said he still learned something new about Philippine fauna upon seeing the new designs.

Johnson & Johnson JNJ announced entering into an exclusive global licensing agreement with Kaken Pharmaceutical to develop, manufacture and commercialize the latter’s STAT6 program for ...

Fauna Bio Inc. has nominated Faun-1083 as its first development candidate, for the treatment of heart failure with preserved ejection fraction (HFpEF). Faun-1083 is a novel small-molecule therapeutic ...

Kymera has recently started a Phase 1 for STAT6 degrader KT-621, while JNJ announced an in-licensing deal with Japan-based Kaken Pharmaceutical for small molecule STAT6 program KP-723, and while ...

Johnson & Johnson gains an exclusive license to Kaken’s STAT6 inhibitor program, including lead candidate KP-723. Kaken will retain the commercialization rights in Japan, where Johnson & Johnson ...

Fauna is decommissioning FQL v4 on June 30, 2025. This driver is not compatible with FQL v10, the latest version. Fauna accounts created after August 21, 2024 must use FQL v10. Ensure you migrate ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...